Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer

Bookmark and Share
Published: 7 Dec 2017
Views: 1421
Rating:
Save
Prof Heikki Joensuu - University of Helsinki, Helsinki, Finland

Prof Joensuu speaks at a SABCS 2017 press session about data from the phase III Synergism or Long Duration (SOLD) clinical trial.

Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment.

Read the news story for more.